Limited Clinical Associations of Age‐Adjusted Serum Thymus and Activation‐Regulated Chemokine in Kawasaki Disease
- 1 January 2026
- journal article
- research article
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70527
Abstract
Background: Kawasaki disease is an acute systemic vasculitis, and the clinical significance of serum thymus and activation‐regulated chemokine (TARC) remains incompletely understood. We examined whether pre‐treatment age‐adjusted serum TARC was associated with inflammation‐based intravenous immunoglobulin (IVIG) resistance risk stratification. Methods: We retrospectively studied 109 children with Kawasaki disease after excluding documented allergic comorbidities and age younger than 6 months. All included patients had serum TARC measured before initial treatment, and 18 of them also had paired post‐treatment measurements. Serum values were expressed as the percentage of the age‐specific upper limit of normal. The primary analysis compared pre‐treatment values between high‐ and low‐risk groups according to the Kobayashi score. Paired pre‐ and post‐treatment changes and exploratory analyses of other IVIG resistance risk scores and treatment non‐response were also assessed. Results: Twenty children were classified as high risk by the Kobayashi score. Pre‐treatment age‐adjusted values were lower in the high‐risk group than in the low‐risk group, but logistic regression analysis did not support a statistically robust association. In 18 children with paired samples, values decreased significantly after treatment. Exploratory analyses showed no significant associations with other IVIG resistance risk scores, whereas analyses of treatment non‐response and coronary artery lesions were limited by the small number of events. Conclusions: Age‐adjusted serum TARC showed limited clinical associations during the acute phase of Kawasaki disease and was not robustly associated with inflammation‐based high‐risk classification. Its role in treatment response and coronary artery outcomes remains to be clarified.Keywords
This publication has 14 references indexed in Scilit:
- Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic ApproachesAnnual Review of Medicine, 2026
- English version of clinical practice guidelines for the management of atopic dermatitis 2024The Journal of Dermatology, 2024
- Revision of diagnostic guidelines for Kawasaki disease (6th revised edition)Pediatrics International, 2020
- Elevated umbilical cord serum TARC/CCL17 levels predict the development of atopic dermatitis in infancyClinical & Experimental Allergy, 2010
- Serum measurement of thymus and activation‐regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age‐specific analysis in atopic dermatitisPediatric Allergy and Immunology, 2009
- Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatmentEuropean Journal of Pediatrics, 2006
- Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseasesJournal of Dermatological Science, 2006
- Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki diseaseThe Journal of Pediatrics, 2006
- Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmaticsAllergy, 2002
- Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokineInternational Immunology, 1999